Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Recruiting 3Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Colorectal Neoplasms 79Stomach Neoplasms 66Rectal Neoplasms 39Pancreatic Neoplasms 29Colonic Neoplasms 27Esophageal Neoplasms 24Lymphoma, Large B-Cell, Diffuse 20Neoplasms 19Adenocarcinoma 19Neoplasm Metastasis 16Cholangiocarcinoma 15Adenocarcinoma Of Esophagus 14Carcinoma, Non-Small-Cell Lung 12Biliary Tract Neoplasms 12Ovarian Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Gastrointestinal Neoplasms 7Gallbladder Neoplasms 7Carcinoma, Hepatocellular 7Locally Advanced Rectal Cancer 6Esophageal Squamous Cell Carcinoma 6Endometrial Neoplasms 6Triple Negative Breast Neoplasms 4Recurrence 4Lymphoma 4Lung Neoplasms 4Carcinoma 4Bile Duct Neoplasms 4Advanced Solid Tumors 4Squamous Cell Carcinoma of Head and Neck 3

Interventions

Cyclophosphamide 49fludarabine 36Dexamethasone 35venetoclax 29pembrolizumab 26Rituximab 21Lenalidomide 18pomalidomide 17Gemcitabine 17fludarabine phosphate 15Etoposide 14Cytarabine 13daratumumab 11carfilzomib 11Temozolomide 11Cisplatin 10Calcium Dobesilate 10glofitamab 9Nivolumab 9Injections 9Azacitidine 9selinexor 8Vincristine 8Carboplatin 8Bortezomib 8obinutuzumab 7Immunotherapy, Adoptive 7Bevacizumab 7zanubrutinib 6ruxolitinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recurrence × Oxaliplatin × 1 year × Clear all
NCT06806033 2026-05-26

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Hoffmann-La Roche

Phase 2 Recruiting
100 enrolled
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04984837 2026-04-20

Study of Lacutamab in Peripheral T-cell Lymphoma

The Lymphoma Academic Research Organisation

Phase 2 Recruiting
56 enrolled
Lymphoid

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Karyopharm Therapeutics Inc

Phase 1/2 Withdrawn
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07001540 2025-06-19

Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation

Fudan University

Phase 2 Recruiting
130 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡